 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for FBXO39 |
 Gene summary |
| Basic gene information | Gene symbol | FBXO39 |
| Gene name | F-box protein 39 | |
| Synonyms | CT144|Fbx39 | |
| Cytomap | UCSC genome browser: 17p13.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_153230.2, | |
| Description | F-box only protein 39 | |
| Modification date | 20141211 | |
| dbXrefs | MIM : 609106 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000177294 | ||
| HPRD : 16444 | ||
| Vega : OTTHUMG00000102062 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_FBXO39 | |
| BioGPS: 162517 | ||
| Pathway | NCI Pathway Interaction Database: FBXO39 | |
| KEGG: FBXO39 | ||
| REACTOME: FBXO39 | ||
| Pathway Commons: FBXO39 | ||
| Context | iHOP: FBXO39 | |
| ligand binding site mutation search in PubMed: FBXO39 | ||
| UCL Cancer Institute: FBXO39 | ||
| Assigned class in TissGDB* | C | |
| Included tissue-specific gene expression resources | HPA,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
| Reference showing the relevant tissue of FBXO39 | ||
| Description by TissGene annotations | ||
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID |
| Top |
| TissGeneExp for FBXO39 |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| HNSC | -0.020464205 | -1.154201415 | 1.133737209 | 1.85E-05 | 9.86E-05 |
| KIRC | -1.15013646 | -2.340760071 | 1.190623611 | 4.55E-14 | 2.15E-13 |
| ESCA | -0.172980273 | -1.450307546 | 1.277327273 | 0.00644 | 0.046805752 |
| Top |
| TissGene-miRNA for FBXO39 |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for FBXO39 |
| TissGeneSNV for FBXO39 |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.E419K | SKCM | 2 |
| p.W46* | SKCM | 2 |
| p.E419K | KIRC | 1 |
| p.F288S | UCEC | 1 |
| p.E3K | SKCM | 1 |
| p.M49I | SKCM | 1 |
| p.S364F | SKCM | 1 |
| p.Q279K | BRCA | 1 |
| p.P10L | SKCM | 1 |
| p.T253A | OV | 1 |
| p.R190K | SKCM | 1 |
| p.R297P | LUAD | 1 |
| p.E54G | LIHC | 1 |
| p.R297C | UCEC | 1 |
| p.W30* | UCEC | 1 |
| p.Y166C | COAD | 1 |
| p.R87H | COAD | 1 |
| p.C245Y | UCEC | 1 |
| p.W46X | SKCM | 1 |
| p.L283P | SKCM | 1 |
| p.P307S | SKCM | 1 |
| p.Y295C | PRAD | 1 |
| p.E74K | BLCA | 1 |
| p.I363M | COAD | 1 |
| p.H207Y | BLCA | 1 |
| p.Y233C | LUAD | 1 |
| p.Q132X | SKCM | 1 |
| p.K294E | UCEC | 1 |
| p.I373S | UCS | 1 |
| p.W273L | ESCA | 1 |
| p.R252W | HNSC | 1 |
| p.Y233F | LUAD | 1 |
| p.W80R | LGG | 1 |
| p.R34K | SKCM | 1 |
| p.E412K | BRCA | 1 |
| p.G265R | SKCM | 1 |
| p.C394Y | PRAD | 1 |
| p.N168K | OV | 1 |
| p.L92Q | LUAD | 1 |
| p.Q132R | STAD | 1 |
| p.S237F | LGG | 1 |
| p.Y370N | STAD | 1 |
| p.R384W | STAD | 1 |
| p.L89V | LUAD | 1 |
| p.E6X | ESCA | 1 |
| p.M97I | BLCA | 1 |
| p.N350S | LIHC | 1 |
| p.Q132* | SKCM | 1 |
| p.D2N | SKCM | 1 |
| p.R300Q | CESC | 1 |
| p.R138H | SKCM | 1 |
| p.G65V | LUAD | 1 |
| p.F85L | HNSC | 1 |
| Top |
| TissGeneCNV for FBXO39 |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for FBXO39 |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Top |
| TissGeneNet for FBXO39 |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| Top |
| TissGeneProg for FBXO39 |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for FBXO39 |
| TissGeneDrug for FBXO39 |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for FBXO39 |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |